AstraZeneca’s Ambitious Plans For Alexion
New HQ In Kendall Square
Executive Summary
The UK major’s CEO, Pascal Soriot, said the setting-up of a new R&D hub in Cambridge, MA, which will also serve as the new corporate headquarters for Alexion, is "a milestone moment" for the rare diseases unit.
You may also be interested in...
Analysts Admire Argenx's Vyvgart Launch
The generalized myasthenia gravis-approved drug passed the $20m mark in sales for the first quarter, comfortably surpassing analyst estimates.
AstraZeneca Clears Ultomiris Overhang With Patent Settlement
The company will pay Chugai $775m to settle a patent dispute related to the complement 5 inhibitor Ultomiris, which it acquired from Alexion.
Nearly Nine Years In The Making, AstraZeneca Finally Unveils New Cambridge R&D Hub
After an expensive and protracted construction, AstraZeneca hopes its Cambridge research center will help foster collaboration and extend its run of R&D success.